Lipoprotein(a) Testing and Management

Introduction to Lp(a) Testing

The European Society of Cardiology recommends checking lipoprotein(a) [Lp(a)] in patients with a family history of premature coronary artery disease (CAD) and personal history of myocardial infarction (MI), as elevated Lp(a) is a significant independent risk factor that requires specific management strategies 1, 2
Elevated Lp(a) (≥50 mg/dL or ≥125 nmol/L) constitutes a significant risk-enhancing factor for atherosclerotic cardiovascular disease, especially in patients with premature CAD and personal history of MI 3

Patients with both elevated Lp(a) and LDL cholesterol have been shown to be at a 10-fold or higher risk of MI compared to those with normal levels 1
The American College of Cardiology suggests that Lp(a) is considered a causal risk factor for cardiovascular disease, including coronary atherosclerosis, aortic valvular stenosis, and ischemic stroke 2

Lp(a) measurement is specifically recommended in patients with premature cardiovascular disease without evident risk factors 1
The American College of Cardiology recommends Lp(a) measurement in individuals with a family history of premature CAD 2, 4
Lp(a) measurement is also recommended in patients with personal history of MI, especially those with recurrent or rapidly progressive vascular disease 1

Traditional thresholds for elevated Lp(a) are >30 mg/dL or >75 nmol/L, which approximate the 75th percentile in white populations 2, 4
The European Society of Cardiology/European Atherosclerosis Society suggests that Lp(a) risk is significant when levels are >50 mg/dL (~100-125 nmol/L) 2, 4

Aggressive LDL-cholesterol reduction should be the first priority, with lower LDL-C goals for patients with elevated Lp(a) 5, 6
The ATP-III guidelines recommend that high Lp(a) counts as an additional risk factor that justifies a lower goal for LDL-C 5, 6
PCSK9 inhibitors have shown modest Lp(a)-lowering effects and should be considered in high-risk patients not reaching LDL-C goals with statins 1

For patients on drug treatment for elevated Lp(a), measurement should be repeated at regular intervals to assess treatment efficacy 1
Regular monitoring of overall cardiovascular risk factors is essential, as Lp(a) is one component of a broader risk profile 3